Tags

Type your tag names separated by a space and hit enter

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Eur J Clin Pharmacol 2004; 60(8):531-9EJ

Abstract

OBJECTIVE

To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD).

METHODS

In four randomised crossover studies, patients with symptoms of GERD received once-daily treatment with esomeprazole 40 mg or lansoprazole 30 mg (study A), omeprazole 20 mg (study B), pantoprazole 40 mg (study C) and rabeprazole 20 mg (study D) for 5 days. Continuous 24-h intragastric pH recording was performed on days 1 (except study B) and 5. Percentage of time over 24 h with intragastric pH greater than 4, 24-h median pH and the proportion of patients with pH greater than 4 for greater than or equal to 12 h and 16 h during the 24-h recording periods were investigated.

RESULTS

In all four studies, esomeprazole 40 mg OD maintained intragastric pH greater than 4 for a significantly higher mean percentage of the 24-h period compared with all other proton pump inhibitors (PPIs) on days 1 (esomeprazole 40.6% versus lansoprazole 33.4%, P=0.0182; esomeprazole 50.3% versus pantoprazole 29.1%, P<0.001; esomeprazole 41.0% versus rabeprazole 29.4%, P=0.002) and 5 (esomeprazole 57.7% versus lansoprazole 44.5%, P<0.0001; esomeprazole 69.8% versus omeprazole 43.7%, P<0.0001; esomeprazole 67.0% versus pantoprazole 44.8%, P<0.001; esomeprazole 59.4% versus rabeprazole 44.5%, P<0.0001). Higher 24-h median pH and a higher proportion of patients with intragastric pH greater than 4 for greater than or equal to 12 h and 16 h were reported with esomeprazole 40 mg OD than with all the other PPIs in each study.

CONCLUSION

Esomeprazole 40 mg provides greater acid control in more patients and maintains intragastric pH greater than 4 for a longer period than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with symptoms of GERD.

Authors+Show Affiliations

Experimental Medicine, Astrazeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden. Kerstin.Rohss@astrazeneca.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15349707

Citation

Röhss, Kerstin, et al. "Esomeprazole 40 Mg Provides More Effective Intragastric Acid Control Than Lansoprazole 30 Mg, Omeprazole 20 Mg, Pantoprazole 40 Mg and Rabeprazole 20 Mg in Patients With Gastro-oesophageal Reflux Symptoms." European Journal of Clinical Pharmacology, vol. 60, no. 8, 2004, pp. 531-9.
Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531-9.
Röhss, K., Lind, T., & Wilder-Smith, C. (2004). Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. European Journal of Clinical Pharmacology, 60(8), pp. 531-9.
Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 Mg Provides More Effective Intragastric Acid Control Than Lansoprazole 30 Mg, Omeprazole 20 Mg, Pantoprazole 40 Mg and Rabeprazole 20 Mg in Patients With Gastro-oesophageal Reflux Symptoms. Eur J Clin Pharmacol. 2004;60(8):531-9. PubMed PMID: 15349707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. AU - Röhss,Kerstin, AU - Lind,Tore, AU - Wilder-Smith,Clive, Y1 - 2004/09/02/ PY - 2003/04/14/received PY - 2004/05/27/accepted PY - 2004/9/7/pubmed PY - 2005/2/4/medline PY - 2004/9/7/entrez SP - 531 EP - 9 JF - European journal of clinical pharmacology JO - Eur. J. Clin. Pharmacol. VL - 60 IS - 8 N2 - OBJECTIVE: To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD). METHODS: In four randomised crossover studies, patients with symptoms of GERD received once-daily treatment with esomeprazole 40 mg or lansoprazole 30 mg (study A), omeprazole 20 mg (study B), pantoprazole 40 mg (study C) and rabeprazole 20 mg (study D) for 5 days. Continuous 24-h intragastric pH recording was performed on days 1 (except study B) and 5. Percentage of time over 24 h with intragastric pH greater than 4, 24-h median pH and the proportion of patients with pH greater than 4 for greater than or equal to 12 h and 16 h during the 24-h recording periods were investigated. RESULTS: In all four studies, esomeprazole 40 mg OD maintained intragastric pH greater than 4 for a significantly higher mean percentage of the 24-h period compared with all other proton pump inhibitors (PPIs) on days 1 (esomeprazole 40.6% versus lansoprazole 33.4%, P=0.0182; esomeprazole 50.3% versus pantoprazole 29.1%, P<0.001; esomeprazole 41.0% versus rabeprazole 29.4%, P=0.002) and 5 (esomeprazole 57.7% versus lansoprazole 44.5%, P<0.0001; esomeprazole 69.8% versus omeprazole 43.7%, P<0.0001; esomeprazole 67.0% versus pantoprazole 44.8%, P<0.001; esomeprazole 59.4% versus rabeprazole 44.5%, P<0.0001). Higher 24-h median pH and a higher proportion of patients with intragastric pH greater than 4 for greater than or equal to 12 h and 16 h were reported with esomeprazole 40 mg OD than with all the other PPIs in each study. CONCLUSION: Esomeprazole 40 mg provides greater acid control in more patients and maintains intragastric pH greater than 4 for a longer period than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with symptoms of GERD. SN - 0031-6970 UR - https://www.unboundmedicine.com/medline/citation/15349707/Esomeprazole_40_mg_provides_more_effective_intragastric_acid_control_than_lansoprazole_30_mg_omeprazole_20_mg_pantoprazole_40_mg_and_rabeprazole_20_mg_in_patients_with_gastro_oesophageal_reflux_symptoms_ L2 - https://dx.doi.org/10.1007/s00228-004-0804-6 DB - PRIME DP - Unbound Medicine ER -